GT Biopharma (GTBP) EV to EBITDA (2010 - 2026)

GT Biopharma (GTBP) has reported EV to EBITDA for 17 consecutive years, with 2.96 the latest figure, recorded in Q1 2026.

• On a quarterly basis, EV to EBITDA rose 155.7% year-over-year to 2.96 in Q1 2026; TTM through Mar 2026 was 0.63, a 273.17% increase from a year earlier, with the FY2025 full-year figure at 0.31, up 17.15% from the prior year.
• EV to EBITDA was 2.96 for Q1 2026 at GT Biopharma, up from 0.68 in the prior quarter.
• Over five years, EV to EBITDA peaked at 9.29 in Q3 2023 and troughed at 0.68 in Q4 2025.
• A 5-year average of 3.71 and a median of 2.96 in 2026 frame the typical range for EV to EBITDA.
• Across the five-year window, EV to EBITDA surged 428.19% in 2022 and tumbled 81.17% in 2024, its largest moves.
• Over 5 years, EV to EBITDA stood at 2.66 in 2022, then jumped by 61.09% to 4.28 in 2023, then slumped by 76.58% to 1.0 in 2024, then sank by 31.86% to 0.68 in 2025, then surged by 334.09% to 2.96 in 2026.
• The last three EV to EBITDA figures came in at 2.96 (Q1 2026), 0.68 (Q4 2025), and 0.75 (Q3 2025), per Business Quant data.